Multicenter Experience using Ledipasvir/Sofosbuvir ± RBV to Treat HCV GT 1 Relapsers after Simeprevir and Sofosbuvir Treatment.

CONCLUSIONS: Treatment with LDV/SOF with/without RBV for 12-24 weeks was very well tolerated and resulted in high SVR 12 rates (96%) in HCV GT1 relapsers to SMV + SOF treatment. PMID: 31104796 [PubMed - in process]

https://www.ncbi.nlm.nih.gov/pubmed/31104796?dopt=Abstract

Source: Annals of Hepatology - May 23, 2019 Category: Gastroenterology Tags: Ann Hepatol Source Type: research